LISATA THERAPEUTICS INC(LSTA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LSTA LISATA THERAPEUTICS INC

休市中 11-06 16:00:00 EST

1.03

+0.04

+3.88%

盘后1.03

+0.000.00%

16:57 EST

最高1.06	最低0.9900	成交量1.51万
今开1.02	昨收0.9915	日振幅7.06%
总市值1,113万	流通市值883.91万	总股本1,080万
成交额1.55万	换手率0.18%	流通股本858.17万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LSTA","market":"US","secType":"STK","nameCN":"LISATA THERAPEUTICS INC","latestPrice":1.03,"timestamp":1793998800000,"preClose":0.9915,"halted":0,"volume":15114,"hourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.03,"latestTime":"16:57 EST","volume":176,"amount":190.03,"timestamp":1794002262381,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03883005547150779,"floatShares":8581675,"shares":10804100,"eps":-1.641822,"marketStatus":"休市中","change":0.0385,"latestTime":"11-06 16:00:00 EST","open":1.02,"high":1.06,"low":0.99,"amount":15505.5342156,"amplitude":0.0706,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.641822,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794214800000},"marketStatusCode":7,"adr":0,"listingDate":1186632000000,"exchange":"NASDAQ","adjPreClose":0.9915,"preHourTrading":{"tag":"盘前","latestPrice":1.01,"preClose":0.9915,"latestTime":"07:20 EST","volume":400,"amount":404,"timestamp":1793967655796,"change":0.0185,"changeRate":0.018659,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.03,"latestTime":"16:57 EST","volume":176,"amount":190.03,"timestamp":1794002262381,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.2858947963454494},"requestUrl":"/m/hq/s/LSTA","defaultTab":"news","newsList":[{"id":"1198844816","title":"Lisata Therapeutics投资者将获得每股1,491.37美元的15万零867.995股C系列优先股","url":"https://stock-news.laohu8.com/highlight/detail?id=1198844816","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198844816?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:34","pubTimestamp":1789652062,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics的投资者即将迎来一项重大权益分配——他们将收到总计150,867.995股C系列优先股，每股作价1,491.37美元。从交易执行角度看，每股1,491.37美元的定价方案已获董事会批准，预计将在既定时间框架内完成结算流程。此次分配完成后，公司总股本结构将发生相应变化，现有普通股股东的稀释效应有待进一步评估。Lisata Therapeutics作为一家专注于创新癌症疗法的生物制药企业，其股价近期的波动走势与行业政策环境、临床试验数据等因素紧密相连。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181729718","title":"Lisata Therapeutics交易后股权结构揭晓：Lisata原股东持2.39%，Marea股东持59.54%，投资者持38.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181729718","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181729718?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:28","pubTimestamp":1789651693,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics近期完成了一项重大交易，其股权结构随之发生了显著变化。据最新披露的数据显示，在这笔交易尘埃落定之后，Lisata Therapeutics原有股东在公司普通股中的持股比例已降至2.39%。与此同时，Marea股东则占据了绝对主导地位，其持股比例高达59.54%。此外，参与此次交易的投资者群体合计持有公司38.07%的普通股。整体而言，这一股权分配方案，将为Lisata Therapeutics未来的公司治理、决策机制以及资本运作，奠定一个全新的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101487698","title":"Lisata Therapeutics：全股票交易收购方案，涉及普通股与C轮优先股","url":"https://stock-news.laohu8.com/highlight/detail?id=1101487698","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101487698?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:28","pubTimestamp":1789651690,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics宣布了一项收购计划，该交易被设计为全股票交易，具体将采用Lisata普通股及C轮优先股作为对价方式。这一结构安排意味着，收购方将通过换股形式完成整合，而非现金支付。值得注意的是，此次交易中，Lisata的普通股与C轮优先股均扮演了关键角色，二者共同构成了交易的对价基础。这一决策，无疑为股东们提供了另一种价值实现的途径——通过持有合并后实体的股份来分享未来增长成果。整个交易方案，从设计之初便体现了对现有股东利益的考量，力求在资本结构上实现平稳过渡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143952601","title":"Lisata Therapeutics拟动用净收益推进MAR001/005与MAR002项目，二期关键数据预计2027年第四季度揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1143952601","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143952601?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:28","pubTimestamp":1789651690,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics宣布，将通过动用本次募资所得净收益，全力推进旗下两大核心管线——MAR001/005及MAR002的临床研发进程。根据公司披露的时间表，上述两项在研疗法的二期临床试验顶线数据，预计将在2027年第四季度对外公布。截至目前，Lisata并未透露更多关于资金分配的具体细节，但明确表示净收益将优先用于支撑上述临床项目的推进，以确保关键里程碑的如期达成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188029638","title":"Lisata Therapeutics宣布收购Marea Therapeutics并同步完成2.25亿美元私募融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1188029638","media":"美股速递","labels":["shareholding","corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188029638?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:27","pubTimestamp":1789651636,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics今日正式对外宣布，公司已就收购Marea Therapeutics达成最终协议。与此同时，该公司还顺利敲定了一笔总额高达2.25亿美元的同步私募融资安排。从战略层面审视，收购Marea Therapeutics无疑是Lisata布局未来的一大步棋。通过整合双方资源与技术平台，Lisata有望在相关治疗领域构筑起更为坚实的竞争壁垒。未来，随着整合工作的有序推进，Lisata Therapeutics将如何续写其创新药开发的新篇章，各界正拭目以待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195250038","title":"Lisata Therapeutics董事会持续评估战略选项，旨在提升股东价值","url":"https://stock-news.laohu8.com/highlight/detail?id=1195250038","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195250038?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:02","pubTimestamp":1785841335,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics董事会，正持续审视各类战略替代方案，核心目标在于为股东创造更大价值。这一进程，不仅展现了公司对资本配置的审慎态度，更映射出其对市场动态的敏锐洞察。在竞争激烈的生物医药领域，此类评估往往成为企业转型或价值重估的关键节点。未来，无论是通过并购、资产剥离，还是业务重组，任何决策都将以股东利益最大化为核心导向。目前，董事会正深入分析多种可能性，以确保持续优化公司结构，进而释放其潜在价值。这一举措，无疑为市场注入了新的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157880865","title":"Lisata Therapeutics 预估：截至2026年9月30日季度内，裁员相关成本达120万美元——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1157880865","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157880865?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:11","pubTimestamp":1785838281,"startTime":"0","endTime":"0","summary":"据美国证券交易委员会（SEC）文件披露，Lisata Therapeutics（证券代码：LSTA）对其财务状况进行了最新预估。该公司预计，在截至2026年9月30日的季度内，与其裁员计划相关的总成本将高达120万美元。这一数字涵盖了此次人力资源调整所产生的各项直接与间接费用，正式揭开了企业战略收缩下的财务影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150579973","title":"Lisata Therapeutics 于7月31日就Kuva Labs及Kuva Acquisition Corp.违反合并协议提起法律诉讼——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1150579973","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150579973?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:11","pubTimestamp":1785838270,"startTime":"0","endTime":"0","summary":"LISATA THERAPEUTICS INC（股票代码：LSTA）——根据其向美国证券交易委员会提交的文件，该公司已于7月31日正式启动法律程序，针对Kuva Labs与Kuva Acquisition Corp.违反合并协议的行为提起诉讼。此项行动标志着双方合作破裂后的法律升级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186569662","title":"Lisata Therapeutics宣布：自2026年8月3日起，终止Kristen K. Buck研发执行副总裁兼首席医疗官职务——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1186569662","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186569662?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:10","pubTimestamp":1785838210,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics（公司名：LISATA THERAPEUTICS INC）——据美国证券交易委员会（SEC）最新提交的文件显示，该公司已正式决定，自2026年8月3日起，终止Kristen K. Buck担任的研发执行副总裁（Evp of R&D）兼首席医疗官（Chief Medical Officer）职务。此举标志着公司高层管理团队的重大调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199900895","title":"Lisata Therapeutics裁员约72% 即刻生效——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1199900895","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199900895?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:09","pubTimestamp":1785838157,"startTime":"0","endTime":"0","summary":"据美国证券交易委员会（SEC）文件显示，Lisata Therapeutics于8月3日批准了一项大规模裁员计划。该计划将裁减约72%的员工，且自批准之日起立即生效。这一削减力度极为显著，涉及公司内部多个岗位。目前，公司并未透露此次裁员的具体原因及后续补偿方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186264845","title":"Lisata Therapeutics董事会评估战略选项，考虑反向并购或资产出售","url":"https://stock-news.laohu8.com/highlight/detail?id=1186264845","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186264845?lang=zh_cn&edition=full","pubTime":"2026-07-25 00:18","pubTimestamp":1784909889,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics公司于美国证券交易委员会（SEC）提交的文件中披露，其董事会正着手评估一系列战略选项。这些备选方案包括反向并购、资产出售等可能性。此举预示着这家生物制药企业或将迎来重大结构变革。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140137974","title":"Lisata Therapeutics：若满足特定条件，公司将放弃追索25万美元逾期付款的权利——SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1140137974","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140137974?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:36","pubTimestamp":1781004988,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件，生物技术公司Lisata Therapeutics表示，如果满足特定条件，它将放弃就一笔25万美元的逾期付款提出索赔的权利。该文件披露了公司与相关方就付款义务进行的协商与调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157369426","title":"Lisata Therapeutics与Kuva Labs达成和解协议 承诺在2026年5月29日前暂停追索权","url":"https://stock-news.laohu8.com/highlight/detail?id=1157369426","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157369426?lang=zh_cn&edition=full","pubTime":"2026-05-04 18:08","pubTimestamp":1777889296,"startTime":"0","endTime":"0","summary":"根据最新提交的美国证券交易委员会文件显示，生物制药企业Lisata Therapeutics Inc已与Kuva Labs达成具有约束力的法律协议。该协议明确规定，在2026年5月29日之前，Lisata将暂缓对Kuva Labs采取任何形式的索赔追索行动。文件未透露双方争议的具体细节，但明确记载了截止日期具有法律效力。资本市场通常对此类阶段性和解持积极看法，因其能有效避免诉讼成本并维持商业关系的稳定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517466947","title":"Lisata Therapeutics, Inc.2024财年实现净利润-19.99百万美元，同比增加4.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517466947","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517466947?lang=zh_cn&edition=full","pubTime":"2025-03-08 02:00","pubTimestamp":1741370441,"startTime":"0","endTime":"0","summary":"3月8日，Lisata Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-19.99百万美元，同比增加4.08%；其中营业收入为1000000.00美元，每股基本收益为-2.40美元。从资产负债表来看，Lisata Therapeutics, Inc.总负债5.69百万美元，其中短期债务137000.00美元，资产负债比为6.16，流动比率为6.17。机构评级：截至2025年3月8日，当前有3家机构对Lisata Therapeutics, Inc.目标价做出预测，其中目标均价为17.00美元，其中最低目标价为15.00美元，最高目标价为21.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308020042abed9a84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308020042abed9a84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LSTA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517288449","title":"Lisata Therapeutics, Inc.盘中异动 股价大涨8.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517288449","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517288449?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:13","pubTimestamp":1741198384,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日02时13分，Lisata Therapeutics, Inc.股票出现波动，股价急速拉升8.84%。Lisata Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.38%。Lisata Therapeutics, Inc.公司简介：Lisata Therapeutics Inc是一家临床阶段的生物制药公司，致力于发现、开发和商业化用于治疗晚期实体瘤和其他重大疾病的创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306021304963b0d55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306021304963b0d55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514356932","title":"Lisata Therapeutics(LSTA.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.55美元，前值为-0.66美元，预期值为-0.76美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514356932","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514356932?lang=zh_cn&edition=full","pubTime":"2025-02-28 06:00","pubTimestamp":1740693657,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics(LSTA.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.55美元，前值为-0.66美元，预期值为-0.76美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28060048442427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137320550","title":"Lisata Therapeutics 第四季度 GAAP 每股收益 $(0.55) 超出 $(0.79) 的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1137320550","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137320550?lang=zh_cn&edition=full","pubTime":"2025-02-28 06:00","pubTimestamp":1740693652,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics  报告季度每股亏损 $，超出分析师一致预期的 $，超出预期 30.38%。与去年同期每股亏损 $ 相比，这是一种 16.67% 的改善。以上内容来自Benzinga Earnings专栏，原文如下：Lisata $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 30.38 percent. This is a 16.67 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385668","title":"Lisata Therapeutics, Inc.盘中异动 早盘急速拉升5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385668","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385668?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:44","pubTimestamp":1740667494,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时44分，Lisata Therapeutics, Inc.股票出现异动，股价急速拉升5.44%。Lisata Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Lisata Therapeutics, Inc.公司简介：Lisata Therapeutics Inc是一家临床阶段的生物制药公司，致力于发现、开发和商业化用于治疗晚期实体瘤和其他重大疾病的创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224454a2567d97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224454a2567d97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LSTA","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514075859","title":"Lisata Therapeutics, Inc.盘中异动 股价大跌7.28%报2.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514075859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514075859?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:04","pubTimestamp":1740582251,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时04分，Lisata Therapeutics, Inc.股票出现波动，股价急速跳水7.28%。Lisata Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Humacyte Inc C/Wts 27/08/2026 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为4662.94%、160.61%、143.94%，振幅较大的相关个股有Enveric Biosciences, Inc.、Humacyte Inc C/Wts 27/08/2026 、Renovaro Inc.，振幅分别为155.93%、39.47%、29.31%。Lisata Therapeutics, Inc.公司简介：Lisata Therapeutics Inc是一家临床阶段的生物制药公司，致力于发现、开发和商业化用于治疗晚期实体瘤和其他重大疾病的创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262304119893b141&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262304119893b141&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LSTA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514323015","title":"Lisata Therapeutics, Inc.盘中异动 股价大跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514323015","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514323015?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:20","pubTimestamp":1740496831,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时20分，Lisata Therapeutics, Inc.股票出现异动，股价急速跳水5.23%。Lisata Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.83%。Lisata Therapeutics, Inc.公司简介：Lisata Therapeutics Inc是一家临床阶段的生物制药公司，致力于发现、开发和商业化用于治疗晚期实体瘤和其他重大疾病的创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225232032989257c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225232032989257c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LSTA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lisata.com","stockEarnings":[{"period":"1week","weight":0.0098},{"period":"1month","weight":-0.1197},{"period":"3month","weight":-0.0283},{"period":"6month","weight":-0.673},{"period":"1year","weight":-0.5617},{"period":"ytd","weight":-0.4462}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Lisata Therapeutics, Inc.根据美国特拉华州法律在Fidelity Medical Services, Inc.的名义下于1980年9月18日注册成立，并于2006年1月在当前市场开始运营。该公司是一家临床阶段的制药公司，致力于发现、开发和商业化治疗实体瘤和其他重大疾病的创新疗法。该公司的主要研究候选产品LSTA1（原名CEND-1）旨在激活一种新的摄取途径，使联合给药或捆绑的抗癌药物能够更有效地穿透实体瘤。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.263077},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.034282},{"month":3,"riseRate":0.727273,"avgChangeRate":0.051032},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.123948},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.00174},{"month":6,"riseRate":0.636364,"avgChangeRate":0.071367},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.109226},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.042316},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.006983},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.13542},{"month":11,"riseRate":0.5,"avgChangeRate":-0.021473},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.083616}],"exchange":"NASDAQ","name":"LISATA THERAPEUTICS INC","nameEN":"LISATA THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LISATA THERAPEUTICS INC(LSTA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供LISATA THERAPEUTICS INC(LSTA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"LISATA THERAPEUTICS INC,LSTA,LISATA THERAPEUTICS INC股票,LISATA THERAPEUTICS INC股票老虎,LISATA THERAPEUTICS INC股票老虎国际,LISATA THERAPEUTICS INC行情,LISATA THERAPEUTICS INC股票行情,LISATA THERAPEUTICS INC股价,LISATA THERAPEUTICS INC股市,LISATA THERAPEUTICS INC股票价格,LISATA THERAPEUTICS INC股票交易,LISATA THERAPEUTICS INC股票购买,LISATA THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LISATA THERAPEUTICS INC(LSTA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供LISATA THERAPEUTICS INC(LSTA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}